376 related articles for article (PubMed ID: 19780597)
21. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Xie Y; Xu D; Huang B; Ma X; Qi W; Shi F; Liu X; Zhang Y; Xu W
J Med Chem; 2014 Oct; 57(20):8445-58. PubMed ID: 25255388
[TBL] [Abstract][Full Text] [Related]
22. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
[TBL] [Abstract][Full Text] [Related]
23. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
Kar P; Knecht V
J Phys Chem B; 2012 May; 116(21):6137-49. PubMed ID: 22553951
[TBL] [Abstract][Full Text] [Related]
24. Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus.
Shu M; Lin Z; Zhang Y; Wu Y; Mei H; Jiang Y
J Mol Model; 2011 Mar; 17(3):587-92. PubMed ID: 20517627
[TBL] [Abstract][Full Text] [Related]
25. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Rungrotmongkol T; Frecer V; De-Eknamkul W; Hannongbua S; Miertus S
Antiviral Res; 2009 Apr; 82(1):51-8. PubMed ID: 19428595
[TBL] [Abstract][Full Text] [Related]
26. Complexity in influenza virus targeted drug design: interaction with human sialidases.
Chavas LM; Kato R; Suzuki N; von Itzstein M; Mann MC; Thomson RJ; Dyason JC; McKimm-Breschkin J; Fusi P; Tringali C; Venerando B; Tettamanti G; Monti E; Wakatsuki S
J Med Chem; 2010 Apr; 53(7):2998-3002. PubMed ID: 20222714
[TBL] [Abstract][Full Text] [Related]
27. Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
Barrett S; Mohr PG; Schmidt PM; McKimm-Breschkin JL
PLoS One; 2011; 6(8):e23627. PubMed ID: 21858186
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
Bantia S; Upshaw R; Babu YS
Antiviral Res; 2011 Sep; 91(3):288-91. PubMed ID: 21722670
[TBL] [Abstract][Full Text] [Related]
29. Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design.
Gong K; Li L; Wang JF; Cheng F; Wei DQ; Chou KC
Med Chem; 2009 May; 5(3):242-9. PubMed ID: 19442214
[TBL] [Abstract][Full Text] [Related]
30. A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase.
An J; Lee DC; Law AH; Yang CL; Poon LL; Lau AS; Jones SJ
J Med Chem; 2009 May; 52(9):2667-72. PubMed ID: 19419201
[TBL] [Abstract][Full Text] [Related]
31. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Mitrasinovic PM
Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
[TBL] [Abstract][Full Text] [Related]
32. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
Meeprasert A; Khuntawee W; Kamlungsua K; Nunthaboot N; Rungrotmongkol T; Hannongbua S
J Mol Graph Model; 2012 Sep; 38():148-54. PubMed ID: 23079644
[TBL] [Abstract][Full Text] [Related]
33. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
Wang SQ; Du QS; Chou KC
Biochem Biophys Res Commun; 2007 Mar; 354(3):634-40. PubMed ID: 17266937
[TBL] [Abstract][Full Text] [Related]
34. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Abed Y; Baz M; Boivin G
Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of NH
Wang K; Yang F; Wang L; Liu K; Sun L; Lin B; Hu Y; Wang B; Cheng M; Tian Y
Eur J Med Chem; 2017 Dec; 141():648-656. PubMed ID: 29107426
[TBL] [Abstract][Full Text] [Related]
36. Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
Prachanronarong KL; Özen A; Thayer KM; Yilmaz LS; Zeldovich KB; Bolon DN; Kowalik TF; Jensen JD; Finberg RW; Wang JP; Kurt-Yilmaz N; Schiffer CA
J Chem Theory Comput; 2016 Dec; 12(12):6098-6108. PubMed ID: 27951676
[TBL] [Abstract][Full Text] [Related]
37. Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase.
Wang P; Zhang JZ
J Phys Chem B; 2010 Oct; 114(40):12958-64. PubMed ID: 20860351
[TBL] [Abstract][Full Text] [Related]
38. Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
Wang PC; Fang JM; Tsai KC; Wang SY; Huang WI; Tseng YC; Cheng YS; Cheng TJ; Wong CH
J Med Chem; 2016 Jun; 59(11):5297-310. PubMed ID: 27167096
[TBL] [Abstract][Full Text] [Related]
39. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
[TBL] [Abstract][Full Text] [Related]
40. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
McKimm-Breschkin JL; Barrett S
Antiviral Res; 2015 Feb; 114():62-6. PubMed ID: 25499124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
